The results indicated that the MOXD1 expression level of samples in the Rose cohort increased as the risk of death from bladder tumors decreased (Figure 8I), consistent with the results obtained using the IMvigor210 cohort. Here, MOXD1 is linked to urinary bladder neoplasm.